Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

• Autores principales: Maria G. Fencer MD (Autor), Catherine H. Davis MD, MPH (Autor), Jieqi Liu MD (Autor), Mark A. Galan MD (Autor), Kristen R. Spencer DO, MPH (Autor)
• Formato: Libro
• Publicado: SAGE Publishing, 2022-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Here...